Inclusion Criteria:

1. Females aged >= 18 years with previous histologically proven diagnosis of

   • Epithelial ovarian carcinoma
   • Fallopian tube carcinoma
   • Primary serous peritoneal carcinoma requiring treatment with further platinum-based chemotherapy > 6 months after their last cycle.
2. Signed informed consent and ability to comply with the protocol
3. Ability to commence treatment within 2 weeks of randomisation
4. CT or MRI proven relapsed disease (measurable or non-measurable), more than six months since completion of first-line platinum-based chemotherapy
5. ECOG performance status 0-1
6. Life expectancy more than 12 weeks
7. If there is a past history of a solid tumour (other than ovarian cancer), this must have been treated curatively more than five years ago with no evidence of recurrence
8. If prior anthracycline or chest radiotherapy, Left Ventricular Ejection Fraction (LVEF) > institutional lower limit of normal.

9. Adequate bone marrow function

   • Absolute Neutrophil Count (ANC) >= 1.5 x 109/l
   • Platelets (Plt) >= 100 x 109/l
   • Haemoglobin (Hb) >= 9g/dl

10. Adequate liver function

    • Serum bilirubin (BR) ≤ 1.5 x ULN
    • Serum transaminases ≤ 2.5 x ULN

11. Adequate renal function

    • Serum creatinine ≤ 1.5 ULN
    • Urine dipstick for proteinuria <2+.

Exclusion Criteria:

1. Non-epithelial ovarian cancer, including malignant mixed Mullerian tumours and mucinous carcinoma of the peritoneum
2. Poorly controlled hypertension
3. History of inflammatory bowel disease
4. Malignancies other than ovarian cancer within 5 years prior to randomisation, except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer.
5. Previous radiotherapy within 21 days prior to randomisation
6. Treatment with any other investigational agent within 6 weeks prior to entering this trial.
7. Arterial thrombotic event (including transient ischaemic attack [TIA], cerebrovascular accident [CVA) and peripheral arterial embolus) within the previous 12 months.
8. GI impairment that could affect ability to take, or adsorption of, oral medicines including sub acute or complete bowel obstruction
9. Known hypersensitivity to AZD2171 or other VEGF inhibitors
10. Major surgery within 2 weeks before entry into the trial
11. Significant haemorrhage of > 30ml in a single episode within 3 months or any haemoptysis

12. Evidence of severe or uncontrolled cardiac disease

    • Myocardial infarct [MI] or unstable angina within 12 months
    • New York Health Association (NYHA ) ≥ grade 2 congestive heart failure (CHF)
    • Cardiac ventricular arrhythmias requiring medication.
    • History of 2nd or 3rd degree atrioventricular conduction defects.
13. Prolonged QTc (corrected) interval of > 470msec on ECG, or a family history of long QT syndrome.
14. Persisting ≥ Grade 2 CTC toxicity (except alopecia and neuropathy) from previous anti-cancer treatment.
15. History or clinical suspicion of brain metastases or spinal cord compression.
16. Inability to attend or comply with treatment or follow-up scheduling
17. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
18. Fertile women of childbearing potential not willing to use adequate contraception for the duration of trial treatment and at least 6 months after
19. Any other severe uncontrolled medical condition or disease